Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

CKD-828 Drug Interaction Study (Telmisartan)

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: Telmisartan 80mg, S-amlodipine 5mg
Drug: Telmisartan 80mg

First Posted Date: 2011-05-19

Last Posted Date: 2011-09-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 32

Registration Number: NCT01356017

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

CKD-828 Drug Interaction Study (S-amlodipine)

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: S-amlodipine 5mg
Drug: S-amlodipine 5mg,Telmisartan 80mg

First Posted Date: 2011-05-19

Last Posted Date: 2011-08-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01356043

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

CKD-828(80/2.5mg) Pharmacokinetic Study_2nd

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828(FDC)
Drug: Combination Therapy

First Posted Date: 2011-05-12

Last Posted Date: 2011-06-08

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 67

Registration Number: NCT01352689

Drug-drug Interaction Study(CKD-501, Amlodipine)

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-501
Drug: CKD-501 amlodipine
Drug: amlodiopine

First Posted Date: 2011-04-25

Last Posted Date: 2011-08-15

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 25

Registration Number: NCT01341392

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers

Phase 1

Completed

Conditions: Chronic Stable Angina

Interventions: Drug: Dilatrend 64mg capsule

First Posted Date: 2011-04-22

Last Posted Date: 2011-12-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01340248

Locations: 🇰🇷
Kyungpook national university, Daegu, Seoul, Korea, Republic of

CKD-828 (40/5mg) Pharmacokinetic Study

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828
Drug: Combination Therapy

First Posted Date: 2011-04-22

Last Posted Date: 2011-04-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 68

Registration Number: NCT01340131

Locations: 🇰🇷
Inje University Pusan Paik Hospital, Pusan, Korea, Republic of

Drug-drug Interaction Study (CKD-501, Ketoconazole)

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-501, Ketoconazole

First Posted Date: 2011-04-07

Last Posted Date: 2011-06-29

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01330563

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia
Gastrointestinal Stromal Tumors

Interventions: Drug: Glivec 100mg film coated tablet
Drug: Luckyvec 400mg film coated tablet

First Posted Date: 2011-01-06

Last Posted Date: 2012-10-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT01270984

Locations: 🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of

CKD-828(80/2.5mg) Pharmacokinetic Study

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828(FDC)
Drug: Combination Therapy

First Posted Date: 2010-11-23

Last Posted Date: 2011-01-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 65

Registration Number: NCT01246193

Locations: 🇰🇷
Inje Unuversity Pusan Paik Hospital, Pusan, Korea, Republic of

The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea

Phase 1

Completed

Conditions: Healthy Male Volunteer

Interventions: Drug: CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet
Drug: CKD-501 placebo tablet, Glimepiride 4 mg tablet

First Posted Date: 2010-05-28

Last Posted Date: 2010-12-10

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01133431

Locations: 🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy